Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Income from Continuing Operations (2018 - 2019)

DiaMedica Therapeutics' Income from Continuing Operations history spans 2 years, with the latest figure at 2480000.0 for Q4 2019.

  • For Q4 2019, Income from Continuing Operations fell 26.4% year-over-year to 2480000.0; the TTM value through Dec 2019 reached 10649000.0, down 85.72%, while the annual FY2025 figure was 353000.0, 101.44% up from the prior year.
  • Income from Continuing Operations reached 2480000.0 in Q4 2019 per DMAC's latest filing, down from 2448000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 650000.0 in Q1 2018 to a low of 3252000.0 in Q1 2019.